NeuBase Therapeutics Inc
F:O7PA
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth €-0.27 (267% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.5 | €0.16 |
0%
|
| Industry Average | 14.3 | €-0.27 |
-267%
|
| Country Average | 19.6 | €-0.37 |
-330%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
NeuBase Therapeutics Inc
F:O7PA
|
107.5m EUR | -8.5 | -9.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -191 955.6 | -159 901.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD | 23.9 | 174.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD | 14.8 | 25.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD | 16.2 | 23.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD | 26.1 | 33.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -566.3 | -534.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD | 16.2 | 18.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD | 14.4 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR | 59.5 | 33.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.2 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
